<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101334</url>
  </required_header>
  <id_info>
    <org_study_id>CS7017-A-U204</org_study_id>
    <nct_id>NCT01101334</nct_id>
  </id_info>
  <brief_title>Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer</brief_title>
  <official_title>Phase 2 Study of CS-7017 and Erlotinib in Subjects With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 and open-label (subject will know the treatment he or she is receiving)
      study. The subject will receive either Erlotinib alone or Erlotinib + CS-7017 in this study.

      The study will determine what effect adding CS-7017 to Erlotinib has on safety and length of
      survival in subjects with advanced non-small cell lung cancer who failed the first treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of subjects with progression free survival</measure>
    <time_frame>4-12 months</time_frame>
    <description>Estimate the difference between the proportion of subjects with progression free survival who are treated with the combination of CS-7017/Erlotinib or Erlotinib alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>4-12 months</time_frame>
    <description>estimate the overall survival in both treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>4-12 months</time_frame>
    <description>estimate the overall response rate for the two treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma concentration of CS-7017</measure>
    <time_frame>week 3</time_frame>
    <description>determine the plasma concentration of CS-7017 at scheduled time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number and percentage of subjects reporting Treatment Emergent Adverse Events (TEAE, and treatment-emergent SAEs.</measure>
    <time_frame>4-12 months</time_frame>
    <description>The number and percentage of subjects reporting Treatment Emergent Adverse Events (TEAE) will be summarized by treatment, the worst NCI CTCAE grade, system organ class, and preferred term. Similarly the number and percentage of subjects reporting treatment-emergent SAEs will be summarized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CS-7017 plus erlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>erlotinib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS-7017</intervention_name>
    <description>CS-7017, Two 0.25mg Tablets administered twice daily</description>
    <arm_group_label>CS-7017 plus erlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Erlotinib; One 150mg tablet administered once daily</description>
    <arm_group_label>CS-7017 plus erlotinib</arm_group_label>
    <arm_group_label>erlotinib</arm_group_label>
    <other_name>Tarceva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed stage IIIB or IV NSCLC.

          -  Recurrent disease (either no response to treatment or subsequent relapse after an
             objective response) that has progressed after first line therapy.

          -  Measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)
             Version 1.1 criteria.

          -  ≥ 18 years of age.

          -  ECOG performance status of 0, 1, or 2.

          -  Adequate organ and bone marrow function.

          -  Resolution of any toxic effects of prior therapy (except alopecia) to National Cancer
             Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0
             grade ≤ 1.

          -  Agreement to use effective contraception while on treatment and for at least 3 months
             after end of treatment.

        Exclusion Criteria:

          -  No treatment with anticancer therapy within 4 weeks before study treatment.

          -  No therapeutic or palliative radiation therapy or major surgery within 4 weeks before
             study treatment (except for radiotherapy for brain metastases).

          -  No administration of other thiazolidinediones (TZDs) within 4 weeks before study
             treatment.

          -  No current need for concomitant use of other TZDs during the study.

          -  No uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known
             human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection at
             time of screening.

          -  No history of any of the following conditions within 6 months before initiating study
             treatment: diabetes mellitus requiring treatment with insulin or TZD agents;
             myocardial infarction with significant impairment of cardiac function; severe/unstable
             angina pectoris; coronary/peripheral artery bypass graft; New York Heart Association
             (NYHA) class III or IV congestive heart failure; malabsorption syndrome, chronic
             diarrhea (lasting &gt; 4 weeks), inflammatory bowel disease, or partial bowel
             obstruction.

          -  No pericardial or pleural effusion (eg, requiring drainage) or pericardial involvement
             with the tumor. Subjects with minimal pleural effusion may be eligible upon request by
             Investigator and approval by Sponsor.

          -  Neither pregnant nor breast feeding.

          -  No known EGFR mutations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>DHHA</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum fur Pneumologie und Thoraxchirurgie</name>
      <address>
        <city>Gauting</city>
        <zip>D-82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King George Hospital</name>
      <address>
        <city>Visakhapatnam</city>
        <state>Andhra Pradesh</state>
        <zip>530002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vedanta Institute of Medical Sciences</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kodlikeri Memorial Hospital</name>
      <address>
        <city>Aurangabad</city>
        <state>Maharashtra</state>
        <zip>431001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tata Memorial Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noble Hospital</name>
      <address>
        <city>Pune</city>
        <state>Maharastra</state>
        <zip>411 013</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Speciality Hospital</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 035</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meenakshi Mission Hospital</name>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625107</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orchid Nursing Home</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700 054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Gyeonggi-Do</city>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hwasun Hospital</name>
      <address>
        <city>Jeonnam</city>
        <zip>519-763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>India</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2010</study_first_posted>
  <disposition_first_submitted>May 7, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>May 7, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 23, 2014</disposition_first_posted>
  <last_update_submitted>May 7, 2014</last_update_submitted>
  <last_update_submitted_qc>May 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Efatutazone</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

